- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Eli Lilly gets CDSCO panel nod to study anticancer drug Imlunestrant
New Delhi: The drug major, Eli Lilly has got approval from the Subject Expert Committee (SEC) functional under the Central Standard Drug Control Organisation (CDSCO) for the proposed study protocol no. J2J-MC-JZLH dated 15-Jun2022 regarding the anticancer drug Imlunestrant vs standard adjuvant.The approval is conditional on the firm regularly monitoring adverse events, particularly those...
New Delhi: The drug major, Eli Lilly has got approval from the Subject Expert Committee (SEC) functional under the Central Standard Drug Control Organisation (CDSCO) for the proposed study protocol no. J2J-MC-JZLH dated 15-Jun2022 regarding the anticancer drug Imlunestrant vs standard adjuvant.
The approval is conditional on the firm regularly monitoring adverse events, particularly those related to skeletons, and submitting such safety reports to SEC/CDSCO for assessment on an annual basis.
This came after the firm presented the proposed study protocol no. J2J-MC-JZLH dated 15-Jun-2022 before the Committee.
Imlunestrant is a small molecule, selective estrogen receptor degrader (SERD), being developed by Eli Lilly and Company, for the treatment of her2 negative breast cancer.
Also Read:Alkem Gets CDSCO panel nod to manufacture, market antidiabetic FDC Drug
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.